Matteo Scipioni
Synthesis of novel vanillin derivatives: novel multi-targeted scaffold ligands against Alzheimer's disease.
Scipioni, Matteo; Kay, Graeme; Megson, Ian L.; Kong Thoo Lin, Paul
Abstract
Alzheimer’s Disease (AD) is the most common cause of dementia worldwide, normally affecting people aged over 65. Due to the multifactorial nature of this disease, a “multi-target-directed ligands” (MTDLs) approach for the treatment of this illness has generated intense research interest in the past few years. Vanillin is a natural antioxidant and it provides a good starting point for the synthesis of new compounds with enhanced antioxidant properties, together with many biological activities, including ß-amyloid peptide aggregating and acetylcholinesterase inhibiting properties. Here we report novel vanillin derivatives, bearing a tacrine or a naphthalimido moiety. All compounds exhibited improved antioxidant properties using DPPH assay, with IC50 as low as 19.5 µM, FRAP and ORAC assays, with activities up to 1.54 and 6.4 Trolox equivalents, respectively. In addition, all compounds synthesized showed inhibitory activity toward acetylcholinesterase enzyme at µmolar concentrations using the Ellman assay. Computational docking studies of selected compounds showed interactions with both the catalytic anionic site and the peripheral anionic site of the enzyme. Furthermore, these compounds inhibited Aβ(1-42) amyloid aggregation using the fluorometric ThT assay, with compound 4 showing comparable inhibitory activity to the positive control, curcumin. At cellular level compound 4 (1 µM)showed significant protective effects of neuroblastoma SH-SY5Y cell line when treated with hydrogen peroxide (400 µM). In our opinion, vanillin derivatives could provide a viable platform for future development of multi-targeted ligands against AD.
Citation
SCIPIONI, M., KAY, G., MEGSON, I.L. and KONG THOO LIN, P. 2019. Synthesis of novel vanillin derivatives: novel multi-targeted scaffold ligands against Alzheimer’s disease. MedChemComm [online], 10(5), pages 764-777. Available from: https://doi.org/10.1039/c9md00048h
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 5, 2019 |
Online Publication Date | Apr 8, 2019 |
Publication Date | May 1, 2019 |
Deposit Date | Apr 9, 2019 |
Publicly Available Date | Apr 9, 2020 |
Journal | MedChemComm |
Print ISSN | 2040-2503 |
Electronic ISSN | 2040-2511 |
Publisher | Royal Society of Chemistry |
Peer Reviewed | Peer Reviewed |
Volume | 10 |
Issue | 5 |
Pages | 764-777 |
DOI | https://doi.org/10.1039/c9md00048h |
Keywords | Alzheimer’s disease; Synthetic antioxidants; AChE inhibitors; Multitarget-directed ligands; Vanillin derivatives |
Public URL | https://rgu-repository.worktribe.com/output/235897 |
Contract Date | Apr 15, 2019 |
Files
SCIPIONI 2019 Synthesis of novel vanillian
(2.6 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
You might also like
Experimental modelling of Alzheimer’s disease for therapeutic screening.
(2022)
Journal Article
Downloadable Citations
About OpenAIR@RGU
Administrator e-mail: publications@rgu.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search